Drug Profile
PTR 01
Alternative Names: BBP-589; Collagen 7 replacement therapy - Phoenix Tissue Repair; HGT-DEB001; PTR-01; rC7; rCol7; Recombinant collagen VII; SHP-608Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator University of Southern California
- Developer BridgeBio Pharma; Phoenix Tissue Repair
- Class Non-fibrillar collagens; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Collagen type VII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epidermolysis bullosa dystrophica
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 30 Nov 2022 PTR 01 is still in phase II trials for Epidermolysis bullosa dystrophica in USA (Phoenix Tissue Repair pipeline, November 2022)
- 09 Aug 2022 Phoenix Tissue Repair completes a phase IIb extension trial in Epidermolysis bullosa dystrophica in USA (IV) (NCT05143190)